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Elevated serum urate levels can cause gout, an excruciating disease with suboptimal treat-
ment. Previous GWAS identiﬁed common variants with modest effects on serum urate. Here
we report large-scale whole-exome sequencing association studies of serum urate and kidney
function among ≤19,517 European ancestry and African-American individuals. We identify
aggregate associations of low-frequency damaging variants in the urate transporters
SLC22A12 (URAT1; p= 1.3 × 10−56) and SLC2A9 (p= 4.5 × 10−7). Gout risk in rare SLC22A12
variant carriers is halved (OR= 0.5, p= 4.9 × 10−3). Selected rare variants in SLC22A12 are
validated in transport studies, conﬁrming three as loss-of-function (R325W, R405C, and
T467M) and illustrating the therapeutic potential of the new URAT1-blocker lesinurad. In
SLC2A9, mapping of rare variants of large effects onto the predicted protein structure reveals
new residues that may affect urate binding. These ﬁndings provide new insights into the
genetic architecture of serum urate, and highlight molecular targets in SLC22A12 and SLC2A9
for lowering serum urate and preventing gout.
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The kidney has a fundamental role in whole body home-ostasis1. It is essential in ﬁltering blood and activelyreabsorbing and secreting solutes, metabolites and proteins
during tubular passage. The importance of tubular kidney func-
tion is illustrated by the regulation of urate metabolism. Serum
urate is freely ﬁltered by the kidney followed by a complex bal-
ance of tubular reabsorption and secretion2. Many genes that
participate in the tubular reabsorption of urate are primarily
expressed in the kidney2. Elevated serum urate levels, hyperur-
icemia, can cause gout, an excruciating disease that affects 4% of
the U.S. population and up to 10% of high risk populations3,4.
The treatment of gout is suboptimal resulting in recurrent
gout ﬂares5. Our understanding of human physiology and
pathophysiology of both glomerular and tubular kidney function
is still limited. Genetic studies offer the possibility to gain novel
insights into the molecular mechanisms of these kidney-related
traits.
The genetic predisposition to hyperuricemia and kidney
dysfunction is evidenced by monogenic diseases and
population-based studies6,7. Studies of individuals of European
ancestry (EA), serum urate, estimated glomerular ﬁltration rate
(eGFR), a measure of kidney function, and urinary albumin-to-
creatinine ratio (UACR), a measure of kidney damage, have
reported heritabilities of 40–70, 33, and 16%, respectively8–10.
Genome-wide association studies (GWAS) have identiﬁed
common variants for these traits that can account for 8, 5, and
1% of the serum urate, eGFR, and UACR variances, respec-
tively11–13. However, the effect size of each common variant
was modest, and few causal GWAS variants were supported
through experimental evidence, except for the common mis-
sense variant Q141K in ABCG2, which encodes a urate trans-
porter14. Evidence from monogenic diseases and from large-
scale association studies15 support a negative correlation
between variant frequency and effect size, suggesting that the
systematic study of low-frequency variants can identify variants
of larger effect.
Therefore, we aim to identify low-frequency (minor allele
frequency [MAF] 1–5%) or rare (MAF < 1%) variants associated
with serum urate, eGFR, and UACR through whole-exome
sequencing (WES) association studies in up to 19,517 EA and
African-American (AA) individuals, and to translate genetic
associations into mechanistic insights. Here, we identify novel
associations between serum urate and low-frequency damaging
variants in the urate transporters SLC22A12 and SLC2A9,
experimentally validate loss-of-function variants in SLC22A12,
and identify candidate residues important for urate binding in
SLC2A9. These ﬁndings provide new insights into the genetic
architecture of serum urate and gout, and highlight attractive
molecular targets in SLC22A12 and SLC2A9 for lowering of
serum urate and prevention of gout.
Results
Study populations and genomic control of meta-analyses. This
study included up to 19,517 participants (15,821 EA and 3,696
AA) from eight cohorts. The total analyzed sample sizes were
16,189 for serum urate, 6762 for gout, 18,795 for eGFR, and
12,844 for UACR. The mean age in each cohort ranged from 53
to 78 years. The population characteristics of each cohort are
reported in Supplementary Data 1. We analyzed the association
of 781,062 variants with minor allele count (MAC) ≥ 10 identiﬁed
through WES that mapped into 19,549 genes. Genomic control
factors for the primary single-variant meta-analyses ranged from
0.99 to 1.00 and 1.05 to 1.07 for the primary optimal sequence
kernel association test (SKAT-O) meta-analyses.
Summary of the studies of kidney function. The studies of the
kidney function measures, eGFR and UACR, conﬁrmed several
known associations, including the burden of rare variants in
SLC47A1 for eGFR16. Details of post-hoc power analyses, as well
as the eGFR and UACR results are reported in Supplementary
Note 1 and Supplementary Data 2 to 8.
Results of single-variant meta-analysis of serum urate. The
overall single-variant meta-analysis of serum urate levels identi-
ﬁed 16 variants as exome-wide signiﬁcant (p < 7.8 × 10−8, Sup-
plementary Data 9). Of these, 13 variants were common (MAF ≥
5%) and located in known serum urate GWAS loci, including
rs2231142 (Q141K) in ABCG2 (beta: 0.22, p= 2.4 × 10−32; OR
for gout: 2.05, p= 1.7 × 10−15), and other variants in SLC2A9,
ABCG2, GCKR, SLC17A1, and SLC17A414. For the eight exome-
wide signiﬁcant common variants in the SLC2A9 region, analyses
controlling for the GWAS index variant, rs1249874213, among
6545 EA participants of the ARIC study showed effect size
attenuations for all eight variants that ranged from 40 to 67%
(Supplementary Data 10).
Low-frequency coding variants in SLC22A12 and SLC2A9. Two
of the exome-wide signiﬁcant variants were rare, independent mis-
sense variants in SLC22A12 with relatively large effects: rs150255373
(beta=−1.11 SD [~−1.67mg/dL], p= 1.3 × 10−10) and
rs147647315 (beta=−0.74 SD [~−1.11mg/dL], p= 1.1 × 10−10,
Table 1). The variant rs150255373 was observed exclusively in EA
participants, while rs147647315 was observed mainly among AA
participants (70 of 77 copies) and has been reported in the
Human Gene Mutation Database (HGMB) as linked to hypour-
icemia (accession number: CM1110340)17. The novel association
of rs150255373 with serum urate was independent of the reported
GWAS index variant, rs47860713, as demonstrated in conditional
analysis including 6713 EA participants of the ARIC study
(Supplementary Data 10). The secondary analysis on the
Table 1 Novel rare missense variants in SLC22A12 associated with serum urate in the primary single-variant meta-analysis
combining EA and AA individuals
Serum urate Gout
Variant Amino acid
positiona
Alt/ref
allele
Alt. allele
count
Betab SE P-value N Alt allele
count
OR Beta SE P-value N
rs150255373 R325W T/C 34 −1.11 0.17 1.3E-10 15,522 12 0.30 −1.20 1.04 2.5E-01 6762
rs147647315 R434H A/G 77 −0.74 0.12 1.1E-10 13,326 26 1.04 0.04 0.52 9.4E-01 4959
rs150255373 (at 64366298, b37) is exclusive to EA, and rs147647315 (at 64367854, b37) has 70 of 77 copies in AA and has been linked to hypouricemia in HGMD (accession number: CM1110340).
The association between rs14764315 and serum urate in AA is reported in Supplementary Data 9. The directions of association of these two variants were consistent across cohorts. rs150255373 beta:
ARIC EA (-1.29), CHS (-0.91), FHS (-1.12), RS (-0.54), CoLaus (-0.97), not detected in ARIC AA, ERF, and CILENTO. rs147647315 beta: ARIC EA (-0.98), ARIC AA (-0.71), CHS (-1.60), FHS (-0.72), not
detected in RS, ERF, CoLaus, and CILENTO
Alt alternate, ref reference, SE standard error, EA European ancestry, AA African-American
aAmino acid positions are based on the canonical form in UNIPROT (ENSP00000366797)
bBeta is in the unit of one SD of inverse normal transformed serum urate, which is ~1.5 mg/dL
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association of rs150255373 with systolic blood pressure in the
ARIC study did not yield reproducible signiﬁcant associations
(ARIC beta: −8.22, p= 0.03, replication beta: −5.04, p= 0.16,
Supplementary Data 11).
In aggregate, the low-frequency putative damaging variants
(MAF < 5%) in SLC22A12 and SLC2A9 were signiﬁcantly
associated with serum urate levels (SLC22A12: 97 variants,
primary SKAT-O p= 1.3 × 10−56; SLC2A9: 90 variants, primary
SKAT-O p= 4.5 × 10−7, Table 2). All 97 variants in SLC22A12
were rare (MAF < 1%), and 82 of them were associated with lower
serum urate levels (Fig. 1a). In the ARIC study, among 260 rare
allele carriers, 255 carried one and 5 carried two alleles, indicating
that the rare variants were largely independent. In the follow-up
analysis employing separate burden test and SKAT combining all
studies, the association between SLC22A12 and serum urate levels
was clearly more signiﬁcant using the burden test (beta=−0.033,
p= 6.7 × 10−57) than the SKAT (p= 4.0 × 10−19). The signiﬁcant
association of SLC22A12 in the burden test was driven by many
variants because 33 variants could sequentially be removed before
the burden test result was no longer exome-wide signiﬁcant.
Higher CADD score and PhyloP46way primate rank score were
signiﬁcantly associated with larger negative effect sizes of these
rare variants, supporting the potential damaging effects of these
variants (CADD score beta: −0.05, p= 2.3 × 10−7, Fig. 1b;
PhyloP46way primate rank score beta: −0.80, p= 8.1 × 10−3).
The association between the PhastCons46way primate rank score
and rare-variant effect size was also inverse, but not statistically
signiﬁcant (beta: −0.56, p= 0.13). Race-speciﬁc burden test meta-
analyses showed that the aggregate effect size of the rare
SLC22A12 variants in EA and AA were of similar magnitude
(EA: 78 variants, beta: −0.033, p= 2.5 × 10−42; AA: 27 variants,
beta: −0.035, p= 3.2 × 10−16). Supplementary Fig. 1 presents the
potentially damaging rare variants included in primary gene-
based analysis in SLC22A12 as a lollipop plot. Gout risk in
carriers of these rare variants in SLC22A12 was halved in
comparison to non-carriers (burden test OR per copy of variant
carried: 0.50, p= 4.9 × 10−3).
For SLC2A9, the SKAT showed stronger association than the
burden test (SKAT p= 2.3 × 10−7, burden test: beta=−0.004,
p= 0.001). This aggregate association was no longer exome-wide
signiﬁcant (SKAT p= 3.1 × 10−4) when the most strongly
associated single-variant was removed (rs73225891; MAF 2.3%,
beta=−0.15, p= 2.8 × 10−5 in single-variant primary meta-
analysis). Secondary meta-analyses did not identify additional
variants or genes associated with serum urate. All genes
associated with serum urate with a SKAT-O p < 1 × 10−6 in both
primary and secondary meta-analyses are reported in Supple-
mentary Data 12.
Interrogation of primary urate meta-analysis. Among the low-
frequency or rare coding variants in SLC2A9 or SLC22A12 that
were previously reported to be associated with hypouricemia, 14
were found in our study with minor allele count ranging from 1 to
77. Of these, 12 showed associations with lower serum urate levels,
and seven reached nominal statistical signiﬁcance (p < 0.05; Sup-
plementary Data 13). Two low-frequency coding variants in
ABCG2, rs2231137 (V12M) and rs72552713 (Q126X), were
reported to be associated with gout18,19. In our study, rs2231137
was not signiﬁcantly associated with gout (MAF= 4%, OR= 0.91,
p= 0.46), and rs72552713, detected almost exclusively among
individuals of East Asian ancestry, was not observed in our study.
Lastly, the urate- and gout-associated coding variant rs150414818
(c.1580C >G) in ALDH16A120 was associated with urate and gout
in our study (serum urate beta: 0.45 SD, p= 0.003, MAF= 0.16%,
n= 13,776; gout OR= 5.93, p= 0.02, MAF: 0.14%, n= 4,959).
The interrogation of the primary SKAT-O meta-analysis
results identiﬁed HPRT1 at chromosome X as associated with
serum urate levels among 34 genes linked to Mendelian form of
abnormal urate levels (p= 1.4 × 10−3, Supplementary Data 14),
the ﬁrst instance that a gonosomal gene was identiﬁed as
associated with serum urate in population-based studies. Other
interrogations conﬁrmed known associations for common
variants in eight candidate genes. Most of these common
missense variants were in high linkage disequilibrium with the
known GWAS index SNPs. (Supplementary Note 1, Supplemen-
tary Data 15).
Prioritization of rare variants in SLC22A12 (URAT1). To
curate the large number of rare variants identiﬁed in SLC22A12
and prioritize them for experimental studies, we used an
approach that combined bioinformatic and statistic evidence to
anticipate functional signiﬁcance (see Methods and Supplemen-
tary Fig. 2), resulting in the identiﬁcation of R325W, R405C,
T467M, and K536T in the URAT1 transporter encoded by
SLC22A12 (Supplementary Data 16). Figure 2a shows the posi-
tions of these four variants in the topology of URAT1.
SLC22A12 (URAT1) variants show reduced protein abundance.
In comparison to wild-type URAT1, all three variants R325W,
R405C, and K536T showed a signiﬁcant reduction in protein
abundance in transiently transfected HEK293T cells (Fig. 2b,
Table 2 Exome-wide signiﬁcant genes for serum urate in primary SKAT-O meta-analysis of low-frequency (MAF < 5%) putative
damaging variants
Serum urate Gout
Race Number of
variants
SKAT-O
P-Value
Burden
Beta
Burden
SE
Burden
P-Value
SKAT
P-Value
Number of
variants
Burden
OR
Burden
Beta
Burden
SE
Burden
P-Value
SLC22A12
EA and AA 97 1.3E-56 −0.033 0.002 6.7E-57 3.98E-19 60 0.50 −0.700 0.249 4.93E-03
EA 78 5.1E-42 −0.033 0.002 2.5E-42 1.48E-18 48 0.41 −0.894 0.322 5.52E-03
AA 27 6.4E-16 −0.035 0.004 3.2E-16 8.31E-10 15 0.66 −0.412 0.393 2.94E-01
SLC2A9
EA and AA 90 4.5E-07 −0.004 0.001 2.2E-03 2.27E-07 48 0.85 −0.157 0.116 1.73E-01
EA 71 8.5E-07 −0.006 0.002 1.5E-04 4.25E-07 36 0.78 −0.249 0.142 7.92E-02
AA 28 3.50E-02 −0.001 0.003 6.90E-01 2.00E-02 17 1.03 0.024 0.200 9.03E-01
Exome-wide signiﬁcant p-value for SKAT-O= 1.28e-6 (= 0.05/19461 genes with 2 or more variants x2 primary SKAT-O tests)
Burden test for gout was conducted using uniform weight for estimating the effect per variant
SE standard error, EA European ancestry, AA African-American, OR odds ratio, SKAT-O optimal sequence kernel association test
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Fig. 2 Topology and experimental results of four damaging variants in SLC22A12. a Topology of SLC22A12 gene product URAT1 with position of variants
tested marked in red. Also marked are glycosylation sites (blue); conserved domains (green); predicted phosphorylation sites (see Supplementary
Methods; yellow); proposed urate-binding residues (orange); and the PDZ domain binding motif (purple). b Abundance of URAT1 mutant constructs in
HEK293T cells, glycosylation revealed with PNGase, and summary data; n= 4 to 12; ±SEM; *p < 0.0001 (ANOVA with Dunnett’s multiple comparison
test). Each lane represents a separate experiment run, processed, and quantiﬁed in parallel. The line in the image denotes the separation between two
separate blots. c Summary data from Xenopus oocytes accumulation assay using C-14 labeled urate (see methods). URAT1 mediated urate transport rates
with the H2O injected control transport rate subtracted (ﬂux of the H2O injected controls was 4.3 [pmol/oocyte/hr]); n= 10 to 16 oocytes (processed in 5
to 8 pairs); ±SEM; *p < 0.01 (ANOVA with Dunnett’s multiple comparison test). Western blot shows the total abundance of each variant upon equal mRNA
injection; lysates from 4–5 pooled oocytes for each construct. Note: in Xenopus oocytes the URAT1 monomer migrates as a single band unlike what is
observed in HEK293T cells
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Supplementary Fig. 3a, b). This reduced abundance was also
observed for the known human disease mutant T467M and
suggested that some of the molecular defect may be caused by
decreased abundance of transporter protein21. To discern the
mechanism, we ﬁrst evaluated glycosylation of URAT1 as a proxy
for trafﬁcking progress. Each of the variants were maturely gly-
cosylated, indicating a portion of the variant proteins can trafﬁc
at least as far as the trans-Golgi (Fig. 2b and Supplementary
Fig. 4) and were not grossly mis-folded and completely removed
via the ER-associated degradation pathway22. However, the ratio
of maturely glycosylated to immature protein was altered for the
R325W, R405C, and T467M variants as compared to the wild-
type protein, suggesting a partial defect in their maturation and
trafﬁcking (Supplementary Fig. 4b). For R325W, the observation
that the variant protein could gain any complex glycosylation was
unexpected because of the predicted damaging nature of the
rather extreme amino acid substitution in a cytosolic portion of
the protein, which is infrequent across a representative mam-
malian alignment of URAT1 (Supplementary Fig. 5). We there-
fore evaluated whether transient over-expression of R325W may
have obscured a mis-folded fraction, or whether R325W may
instead affect the phosphorylation at the downstream S329. To
test these possibilities, we mutated another arginine in the
intracellular loop 3 (ICL3) that unlike R325 is not predicted to
form a kinase substrate motif, R291 (Supplementary Fig. 4c, d).
The R291W mutant showed very low abundance, and none of the
protein trafﬁcked to the Golgi nor acquired Endo H resistance,
consistent with a severe folding variant that is recognized by the
ER-associated degradation pathway quality control system22. The
lack of an equally profound trafﬁcking defect for R325W as
compared to R291W provides initial evidence that R325W may
disrupt a phosphorylation domain and regulation site of the ICL3.
SLC22A12 (URAT1) variants display altered urate transport.
The mutant URAT1 constructs were expressed in Xenopus oocytes.
Transport function was evaluated using a C-14 radiolabeled urate
accumulation assay with a low Cl− extracellular bath to maximize
URAT1 dependent ﬂux. Xenopus oocytes expressing R325W,
R405C, or the known positive control T467M displayed sig-
niﬁcantly less C-14 urate accumulation than oocytes expressing the
wild-type transporter (Fig. 2c), consistent with the variants causing
a loss-of-function. Mean urate accumulation of K536T in oocytes
was not signiﬁcantly different from that expressing the wild-type
transporter (Fig. 2c). This was unexpected because human variant
carriers showed signiﬁcantly higher serum urate levels. We there-
fore investigated transporter abundance for all variants and found
clearly reduced transporter abundance of K536T (Supplementary
Figs. 3c, 6a). Normalizing urate uptake for transporter abundance
showed signiﬁcantly higher transport rates across three time points
and three different urate concentrations by K536T compared to
wild-type expressing oocytes (Supplementary Fig. 6b). These
observations may suggest that K536T represents a gain of transport
function mutant, which is consistent with its association with higher
urate levels in our association study and could reconcile the dis-
crepancy between the observation in humans and the uptake studies
in oocytes. These ﬁndings need however to be interpreted with
caution, given that protein abundance could not be assessed in
human target tissue. Together, these four rare variants along with
the previously described R434H that was also detected in our study
explained 0.8% of the urate phenotypic variance.
Characterization of SLC2A9 (GLUT9) variants. We employed a
complementary approach for evaluating potential functional con-
sequences of the rare aggregated and urate-associated variants in
SLC2A9 to identify functional areas in the encoded transporter
GLUT9 that may speciﬁcally accumulate rare variants. Capitalizing
on the known structure of a homologous transporter (see Methods),
we mapped SLC2A9 variants with absolute effect sizes > 1.5 standard
deviations on a structural model of GLUT9/SLC2A9b (Fig. 3).
Supplementary Fig. 7 shows all variants with absolute effect >
1 standard deviations on the structural model. Figure 4 presents the
putative damaging variants with MAF < 5% based on the amino
acid position of SLC2A9b. Their localization revealed three hotspots
of potential functional signiﬁcance: the extracellular interface (N61S;
H68Y; S129L; D377N), the intracellular interface (K109N; G249S;
Y478X), and the central core region (F88L; V184M; V428I; N433S).
Both the extracellular and intracellular interface groups include
variants in highly conserved residues with predictable damaging
effects. For example, K109N at the intracellular interface is part of
the canonical GRR/K motif in the short intracellular linker between
the second and third transmembrane helices (Supplementary
Fig. 8a, b). Variants to these or homologous residues in the second
half of the protein (between TM8 and 9; e.g. R380W) cause loss of
urate transport function, as do similar variants in the GRR motif in
other SCL transporters (e.g., the SLC22A12 R405 variant)23,24.
Similarly, N61S on the extracellular interface substitutes the con-
served N-glycosylation site (NXS) homologous across all type I and
type II GLUTs25, and the loss of this asparagine causes signiﬁcant
alterations in afﬁnity and function of related SLC2A transporters26.
Finally, S129L represents a highly disfavored substitution, potentially
impacting the position of the neighboring C128 residue previously
shown to be important for determining urate afﬁnity and transport
capacity27.
A group of particularly high interest includes the variants
mapping to the predicted core helices (F88L; V184M; V428I;
N433S). Previously, Long et al28. deﬁned four residues, Y42,
Q299, G402, and N429, as forming hydrogen bond interactions
with urate in the binding pocket (with the N-O bond distance as
being the typical 3.0 Å; Fig. 3b, c). The distances between the
atoms in the modeled open conﬁguration are altered by each of
the 4 core variants (Fig. 3d, e; Supplementary Fig. 9) resulting in
the loss of one or more of the four predicted hydrogen bonds
between urate and the binding pocket of GLUT9. Interestingly,
each amino acid substitution (88L; 184M; 428I; 433S) is either
favored or neutral, suggesting they may be tolerated within the
structure and yet change subtly the relationship of key residues in
the substrate binding pocket potentially preventing the urate from
binding or binding with altered afﬁnity.
Discussion
Using large-scale WES association studies among up to 19,517 EA
and AA individuals, we conﬁrmed common variants associated
with serum urate, eGFR and UACR and identiﬁed rare urate-
associated variants that mapped into loci previously identiﬁed
through GWAS11,13. The effect sizes of rare urate-associated var-
iants correspond to 1.0 to 1.7mg/dL lower serum urate levels,
which is more than three times larger than the effect size of com-
mon variants identiﬁed in GWAS13. Strikingly, dozens of rare
potentially damaging variants in SLC22A12 and SLC2A9 were
strongly associated with serum urate levels in aggregate, providing
novel insights into the genetic architecture of urate metabolism. The
majority of the rare variants in SLC22A12 were associated with
lower serum urate levels, and carriers showed half the risk of gout
compared to non-carriers. Functional characterization of four rare
variants in SLC22A12 conﬁrmed R325W, R405C, and T467M as
loss-of-function variants. Mapping of SLC2A9 variants onto the
modeled structure of the encoded GLUT9 protein led to the
identiﬁcation of mutation hotspots in speciﬁc functional domains.
The preponderance of urate lowering rather than urate-
increasing variants in URAT1 in our study is consistent with a
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06620-4 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:4228 | DOI: 10.1038/s41467-018-06620-4 |www.nature.com/naturecommunications 5
previous Japanese sequencing study that identiﬁed seven exonic
SLC22A12 variants in patients with low serum urate levels.
However, only one variant was validated in transport studies29.
The large number of loss-of-function variants observed in our
study might be explained by a mechanism that counter-acts the
loss of uricase in humans. The loss of uricase function in humans
results in higher serum urate levels compared to most other
species, which was speculated to have evolutionary beneﬁts
because of several independent mutational events resulting in the
loss of uricase function during hominoid evolution30. Another
explanation for the large number of potential loss-of-function
variants in SLC22A12 and the observation that no rare variants of
large effect were identiﬁed for the other studied kidney function
traits, eGFR, and UACR, could be that these variants have not
been under selection pressure. This is supported by the obser-
vation that the number of rare exonic variants (MAF < 0.1%) in
SLC22A12 did not differ signiﬁcantly from expectation in the
ExAC database31. Tolerance to loss of SLC22A12 function may be
due to the presence of several other transporters that can reabsorb
urate from the tubular lumen such as SLC22A11 (OAT4) and
SLC22A13 (OAT10)32,33. Alternatively, gain-of-function variants
in URAT1 may not be identiﬁed as readily either because they
may have pathogenic effects in early development, or because
individuals with gain-of-function variants may receive urate-
lowering treatment and hence their serum urate levels might not
reﬂect their genetic predisposition. We therefore expect that
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genetic studies among ascertained populations with detailed
information on urate-lowering therapies may yield com-
plementary insights.
In GWAS of serum urate, SLC22A12 is a locus of modest effect
size13. However, in our rare-variant association study, SLC22A12
emerged as a gene containing multiple rare variants with large
effects, with ﬁve rare and experimentally conﬁrmed variants
explaining 0.8% of the serum urate variance. In contrast, SLC2A9
is the locus with the largest effect size in GWAS of serum urate,
explaining ~60% of the genetic effects attributed to all GWAS
index SNPs in EA34, but there were comparatively few rare var-
iants of large effects identiﬁed in our sequencing association
study. These ﬁndings are consistent with a genetic architecture of
serum urate that is dominated by a small number of genes,
namely common variants in SLC2A9 and ABCG2 and multiple
rare variants in SLC22A12. The relative contributions of common
and rare variants in these genes need to be updated as additional
rare variants identiﬁed in our and other studies are experimen-
tally conﬁrmed. As a complex trait, the genetic architecture of
serum urate additionally involves a large number of genetic
variants with modest effects from many genes. The comparison of
the genetic architecture of serum urate to those of other complex
traits and diseases is currently limited by the paucity of large-scale
sequencing association studies of comparable size.
Variants identiﬁed through genetic association studies in
humans are often not translated into mechanistic insights on a
molecular level. We tried to address this common limitation by
the functional study of rare SLC22A12 variants predicted to result
in impaired URAT1 function, which provided new information
on the human URAT1 molecule including new potential target
residues for pharmacological modulation of urate reabsorption.
We conﬁrmed the previously described T467M variant as a loss-
of-function variant21. Using the same methods, we identiﬁed
R325W and R405C as loss-of-function and present ﬁrst evidence
indicating that K536T may show increased transport rates but
coupled with decreased abundance. Because of the use of model
systems to quantify protein abundance, further interpretation
requires understanding of how the K536T variant manifests in
the human target tissues.
The R405C variant is located in the second GRR motif con-
served across the SLC transporter family and is proposed to be
important for positioning the helix that contains the F365 residue,
critical for urate-binding afﬁnity23,35,36. This is supported by
previous work describing the neighboring R406C as a loss-of-
function human disease mutant37. Conversely, the R325W sub-
stitution resides in a cytosolic linker region known to harbor
multiple phosphorylation sites that regulate function in closely
related transporters38. In hURAT1, the downstream S329 residue
is a predicted phosphorylation site, making R325 a potential
critical residue in the substrate recognition motif (REELS) for the
phosphorylating kinase. At this position, glutamine is more fre-
quent across a representative mammalian alignment of URAT1,
excepting representatives of primate linage. Given the
differential afﬁnity and transport capacity for urate between the
apes and other mammals, these discrepant amino acids at posi-
tion R325 may indicate a key alteration in human URAT1
function or regulation. The URAT1 K536T variant occurs in the
C-terminal cytoplasmic tail in an area critical for protein-protein
interactions (PDZ binding motif, S/T-X-Φ) and modiﬁcations
critical for function39. Although the C-terminal tail is not well
conserved across human MTF family members, the SLC22A12 C-
terminus is highly conserved across mammalian species. Like
R325 and R405, K536 is predicted to form a kinase substrate
motif for targeting phosphorylation at T539 and thus could
be critical for proper regulation40. This is supported by our
ﬁndings that the K536T substitution shows signiﬁcantly altered
abundance when heterologously expressed in either oocytes or
HEK293T cells.
Mapping of the SLC2A9 variants on to the modeled protein
structure, a complementary approach to transport studies,
revealed three new potentially key regulatory and functional
domains in GLUT9. We found both the extracellular and intra-
cellular interfaces to be enriched with variants of large effect size,
strongly supporting the role of glycosylation at N61 as critical for
GLUT9 function. In addition we found that the four core var-
iants, F88L, V184M, V428I, and N433S each disrupted predicted
hydrogen bond interactions between urate and four key urate-
binding residues (Y52, Q299, G402, and N42928,41), changes that
may alter the substrate binding kinetics and afﬁnity.
Clinically, the identiﬁcation and experimental conﬁrmation of
functional variants in URAT1 delivers insights into important
regulatory mechanisms of the protein. Insights into the regulation
of URAT1 activity and abundance at the molecular level can
represent a basis for the development of targeted drugs to lower
serum urate. Both hyperuricemia and gout are common condi-
tions, and gout is commonly undertreated42. A clinical trial of
febuxostat and allopurinol, the most commonly used drug to
lower serum urate, showed that only 21% of patients randomly
assigned to 300 mg/d allopurinol achieved optimal serum urate
concentrations43. The development of additional urate-lowering
drugs is therefore of high clinical interest. The ﬁrst URAT1
inhibitor, lesinurad, has just been approved for gout patients with
treatment-resistant hyperuricemia44. The validated loss-of-
function variants we identiﬁed in URAT1 illustrate the ther-
apeutic potential of lesinurad and may provide insights into how
to further develop this medication class. Our results may also aid
in the development of SLC2A9 inhibitors to lower serum urate.
The strengths of our study include the use of WES, which
enabled the detection of rare variants not limited by reference
panels, poor imputation quality, or representation on a micro-
array. Another strength is our experimental approach that used
transport assays as well as abundance and glycosylation studies in
mammalian cells to provide additional insights into the molecular
mechanisms. Some limitations of our study warrant mention.
Several factors may have reduced our ability to detect genetic
associations. First, although whole-exome capture platforms
covered most of the coding regions45, gaps in coverage may have
limited our ability to detect genetic variants in those regions.
Differing genotype quality ﬁlters across cohorts independent of
our phenotypes could also have reduced our ability to detect true
associations. Although this study represents the largest WES
study of serum urate and measures of kidney function to date, the
sample size was still limited for identifying rare variants that
individually show signiﬁcant associations with the evaluated
traits. In addition, the effect size of low-frequency variants
associated with kidney function may be smaller than those
associated with serum urate due to imprecision in GFR estimates
and higher within-person variability46–48. Very rare or private
alleles of large effect may be more readily identiﬁed in referred
patients. In addition, despite WES, a previously replicated and
validated urate-lowering missense variant, rs12800450, was not
present in our sample49. The upcoming data from the large,
trans-ethnic TOPMed Program will provide an additional
opportunity to further investigate the frequency of this variant in
whole genome sequence data. In the present study, while we
conﬁrmed that the variants most likely to be damaging were
indeed loss-of-function variants, the SLC22A12 and SLC2A9
variants were too numerous to allow for comprehensive experi-
mental testing. If some of the rare variants in SLC22A12 and
SLC2A9 were nonfunctional, however, this would lead to an
underestimate of the aggregated effect because the gene-based
tests combined all rare putative damaging variants based on
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annotation. We focused our follow-up investigation on low-
frequency and rare variants. Future functional studies are
required for studying common missense variants found in known
GWAS loci to evaluate their potential causal effect on serum urate
levels since a missense variant in regions implicated by GWAS is
not a direct support for causality50.
In conclusion, this large-scale WES association study delivered
new insights into the genetic architecture of serum urate. It dis-
covered rare, independent urate-associated variants of large effect
as well as conﬁrmed common variants associated with serum
urate, eGFR, and UACR in known GWAS loci in the general
population. Dozens of rare, potentially damaging variants in
SLC22A12 and SLC2A9 were strongly associated with serum urate
levels in aggregate. Risk of gout was halved in carriers of rare
variants in SLC22A12, illustrating the therapeutic potential of the
new URAT1-blocker lesinurad. The R325W and R405C variants
in URAT1 were experimentally validated as new loss-of-function
variants. Mapping of SLC2A9 variants onto the modeled GLUT9
protein structure revealed new potentially key regulatory and
functional domains. These represent a basis for the design of
additional urate-lowering therapies, for which there is a high
clinical need given the rising burden of gout.
Methods
Study populations. The study populations included 15,431 EA and 3698 AA
participants from eight population-based studies: the Atherosclerosis Risk in
Communities study (ARIC), Cardiovascular Health Study (CHS), Cilento study,
CoLaus study, Erasmus Rucphen Family study (ERF), the National Heart, Lung,
and Blood Institute GO Exome Sequencing Project (ESP), Framingham Heart
Study (FHS), and the Rotterdam Study (RS). All studies were approved by their
respective Institutional Review Boards, and all participants provided written
informed consent. Details about the studies have been reported previously, and the
key references as well as the summary of the design of each study are reported in
Supplementary Data 17.
WES and annotation. Details on sequencing, variant calling, and variant quality
control are reported in Supplementary Data 18. Brieﬂy, WES in ARIC, CHS, and
FHS was performed by the Baylor College of Medicine Human Genome Sequen-
cing Center as a part of the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium based on established protocols (Baylor
College of Medicine Human Genome Sequencing Center (BCM-HGSC) protocols
for sequencing library construction, https://www.hgsc.bcm.edu/content/protocols-
sequencing-library-construction, and Mercury analysis pipeline, https://www.hgsc.
bcm.edu/content/mercury)). The CILENTO, CoLAUS, ERF, ESP, and Rotterdam
studies performed WES following similar protocols51,52. The annotation process
combined all variants from each study and annotated variants using ANNOVAR53
and dbNSFP v2.054 based on the reference genome GRCh37 and National Center
for Biotechnology Information RefSeq.
Outcomes. The primary outcomes of this study were the kidney function related
traits: serum urate, eGFR, and UACR. The methods for calculating eGFR were the
same as in previous GWAS of kidney function55. Brieﬂy, the MDRD 4-variable
equation47 was applied to calculate eGFR after serum creatinine levels in each study
were calibrated using age- and sex-speciﬁc means from the nationally repre-
sentative NHANES Survey. Prevalent gout was analyzed as a secondary outcome
for signiﬁcant variants or genes associated with serum urate levels. Gout cases were
ascertained based on self-report. The laboratory methods for measuring serum
urate, serum or urinary creatinine, and urinary albumin are reported in Supple-
mentary Data 17.
Association analysis. Serum urate, eGFR, and UACR were analyzed as continuous
outcomes. Due to their skewed distribution and consistent with previous
studies11,12, natural log transformation was applied to eGFR and UACR. Then
residuals of serum urate, log-transformed eGFR and UACR were generated
adjusting for age, sex, genetic principal components, and study center if applicable.
To minimize potential inﬂuence from outliers, inverse normal transformation was
applied to the residuals, which were used as the outcome in genetic association
analyses. Gout was analyzed as a binary outcome adjusting for age, sex, genetic
principal components, and study center if applicable. Each study generated cohort-
level association summary results based on a linear regression model for serum
urate, eGFR, and UACR, and a logistic regression model for gout using the seqMeta
R package version 1.3. Family studies additionally accounted for relatedness.
Subsequently, the association summary results from each study were combined via
meta-analyses.
An overview of the workﬂow of all meta-analyses and secondary analyses is
depicted in Supplementary Fig. 10. The primary meta-analyses included single-
variant tests and the optimal sequence kernel association test (SKAT-O)56
combining results from all EA and AA studies. The primary single-variant meta-
analysis results were ﬁltered by total minor allele count (MAC) ≥ 10. The primary
SKAT-O meta-analyses included two sets of tests that aggregate low-frequency and
rare putative damaging variants with overall MAF < 1% and < 5%. Putative
damaging variants (predicted to change protein function as described in
MacArthur et al.57) included those annotated as missense, coding insertion-
deletion (indels), and splice sites based on ANNOVAR, predicted splice sites based
on AdaBoost (score ≥ 0.6), SPIDEX (absolute change of psi score ≥ 5), or a method
combining adaptive boosting and random forest (score ≥ 0.6)58–60. Only genes with
two or more putative damaging variants across all studies were included. The
weight for each variant was the default beta distribution with parameters 1 and 25.
Details for the secondary meta-analyses of all traits and follow-up analyses on
urate-associated rare variants and blood pressure are reported in the
Supplementary Methods section and Supplementary Data 19 to 23.
Exome-wide signiﬁcance threshold. The exome-wide signiﬁcance thresholds
were determined by the Bonferroni method based on the number of variants or
genes included in the primary meta-analysis. The signiﬁcance thresholds of the
primary single-variant meta-analyses were 7.8 × 10−8 (= 0.05/640,895 variants) for
serum urate, and 6.4 × 10−8 (= 0.05/781,062 variants) for eGFR and UACR. The
signiﬁcance thresholds of the primary SKAT-O meta-analyses were corrected for
the number of genes with at least two variants and the two sets of tests (MAF < 1%
and < 5%): 1.28 × 10−6 (= 0.05/[19461 genes*2]) for serum urate, and 1.28 × 10−6
(= 0.05/[19549 genes*2]) for eGFR and UACR. We performed post-hoc power
calculations for 80% power to detect the minimum effect size for single variants
with MAF of 0.01, 1, and 5% for the three traits in the overall study population and
in EA and AA separately assuming an alpha of 7.8 × 10−8 to account for multiple
testing.
Follow-up on exome-wide signiﬁcant variants and genes. First, exome-wide
signiﬁcant rare variants that mapped into a previously known GWAS locus and
common variants in the SLC2A9 region were evaluated for their independent
association with the outcome by conditioning on the GWAS index SNP. This
analysis was conducted in the ARIC study, the largest among the contributing
studies. GWAS variants were imputed based on the 1000 Genomes reference panel
phase I version 361. Second, exome-wide signiﬁcant genes from the primary SKAT-
O meta-analysis were evaluated using separate burden test and SKAT to assess the
aggregate direction of association of the rare variants. Third, to determine whether
the signiﬁcant associations using SKAT-O were mainly driven by a small number
of variants per gene, we conducted sensitivity gene-based analysis by successively
removing the variants with the strongest association based on single-variant test
results until the p-value of the gene-based test (burden or SKAT, whichever gen-
erated the association with the lowest p-value) was no longer exome-wide sig-
niﬁcant. Fourth, to gain insight into the predicted consequence of the rare putative
damaging variants in exome-wide signiﬁcant genes, we regressed the PhyloP46way
primate rank score, PhastCons46way primate rank score, and CADD phred score
of these variants against their effect sizes from the primary single-variant meta-
analysis62–64. Finally, we calculated the urate phenotypic variance explained by the
ﬁve rare urate-associated and experimentally conﬁrmed variants from our study or
a previous study (R325W, R405C, T467M*, R434H, K536T) based on their effect
sizes in the primary single-variant analysis17.
Interrogation of known urate-associated rare variants. We systematically
searched the literature (see Supplementary Methods) for low-frequency coding
variants that were reported to be associated with gout or serum urate and retrieved
their association statistics from our primary meta-analysis.
Selection of variants for experimental studies. We prioritized SLC22A12
variants that were most likely to have functional or regulatory effects based on the
long isoform and the corresponding mRNA amino acid sequence (NP_653186; see
protocol depicted in Supplementary Fig. 2 and Supplementary Methods). We
further required that the candidate variants showed nominal association with
serum urate (p < 0.05) and had consistent direction of association among the
cohorts in the overall single-variant meta-analysis of serum urate. Among four
candidate variants selected for study (Supplementary Data 16), rs200104135
(T467M) was selected as a positive control because it was reported in the Human
Gene Mutation Database (HGMD) as a variant for hypouricemia (accession
number: CM139310)21.
Molecular biology. The human SLC22A12 (URAT1) construct in the pcDNA3.1
vector was obtained as described previously49. The SLC22A12 variants (as denoted
in the cDNA of SLC22A12 isoform a, NP_653186.2) R325W, R405C, T467M, and
K536T were created using the QuikChange site-directed mutagenesis kit (Agilent
Technologies, USA) and the primers were ordered from IDT (Integrated DNA
Technologies, USA, sequence in Supplementary Methods). mRNA for injection
and expression in Xenopus oocytes was prepared from the SLC22A12 mutant
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expression vectors using the mMessage mMachine Kit and the MEGAclear kit
(Ambion/Life Technologies, USA) according to the manufacturer’s protocol.
Mammalian cell culture and transfection protocol. Human embryonic kidney
cells (HEK293T, GenHunter Corp, USA) were cultured in DMEM (Life Tech-
nologies/Gibco 11995) supplemented with 10% FBS and 500 mg/ml penicillin & 50
mg/ml streptomycin. Cells were grown to > 90% conﬂuence and plasmids trans-
fected using X-tremeGENE 9 (Roche, GER) according to manufacturer’s protocol.
Western blot protocol. Cells were lysed 48 hours post-transfection using lysis
buffer (1% deoxycholic acid, 1% triton X-100, 0.1% SDS, 150 mM NaCl, 1 mM
EDTA, 10 mM Tris HCl pH 7.5, and protease inhibitor (complete protease inhi-
bitor, Sigma, USA). The samples were incubated at 37°C for 30 min with 5×
laemmli buffer, with 5% 2-beta mecaptoethanol. The samples were run on precast
10% Stain-Free Gels (Biorad, USA), transferred to nitrocellulose membrane using
the Bio-Rad Transblot transfer system (Biorad, USA), and blocked in 5% non-fat
milk. The appropriate primary antibody (anti-SLC22A12; MBL International Corp
(JPN), #BMP064, 1:1000) was added and the membrane was incubated overnight at
4 °C. After washing and the addition of appropriate secondary antibody the
membrane was exposed with Super Signal ECL (Pierce) and the chemiluminesence
signal was captured using a ChemiDoc Imagining system (BioRad, USA) and band
density was calculated using BioRad’s Image Lab Software. Normalization/Loading
controls were done by calculating the total protein loaded in each lane using the
BioRad Stain-Free Gel System. Statistical comparisons of density measurements
from western blots were done with the Student’s t-test for pair wise comparisons,
or an ANOVA, used with a Tukey’s or Dunnett’s Test for multiple comparisons
(Prism 7, GraphPad, USA). All reported means are ± standard error of the mean
(SEM).
Deglycosylation protocol: PNGase F. After 48 h of transfection, the cells were
lysed and total protein harvested and estimated. A volume of 10 μg of total protein
was denatured in 10XG buffer by heating at 100 °C for 10 min. The denatured mix
was then treated with 10XG2, 10% NP-40, PNGase F (NEB, USA), and H20 and
incubated at 37°C for 1 hr. At end of the reaction, the sample was analyzed by
western blot. EndoH: 10 μL of total protein sample was denatured as above. The
denatured mix was then treated with 10XG5, EndoH (NEB, USA), and H20 and
incubated at 37 °C for 1 hr. At end of the reaction, the sample was analyzed by
western blot.
Xenopus oocyte cell expression. Stage V-VI de-folliculated Xenopus laevis
oocytes were obtained from Ecocyte Bioscience US LLC (USA). On the day of
delivery, the oocytes were selected and injected (Nanoinject II, Drummond Sci-
entiﬁc, USA) with 50 nl of either mRNA or with H2O (control). All experiments
were done on the third day after injection. Oocytes after injection were cultured in
a modiﬁed L-15 media (OR-3) and kept at 15–20 °C. Oocyte batches from three
different shipments were used in the western blot and transport experiments.
Western blot protocol for Xenopus oocytes. Three days after injection, 4–5
oocytes per treatment were pooled and placed into a 1.5 ml tube. Ice-cold oocyte
lysis buffer was added (in mM: 20 Tris-HCl, 140 NaCl, 2% Triton-x-100, and
protease inhibitors) and the oocytes were incubated on ice for 30 min. Then the
oocytes were homogenized and spun at 4 °C at 7500 RPM to remove the nucleus,
yolk, and cellular debris. A second incubation period on ice was followed by a ﬁnal
16,000 RPM spin to remove remaining insoluble materials. The cell lysate was then
stored at −80 °C until used for the western blot. SLC22A12 antibody was used to
probe the blot (anti-SLC22A12; MBL International Corp (JPN), #BMP064, 1:1000)
and normalization/loading controls were done by calculating the total protein
loaded in each lane using the BioRad Stain-Free Gel System. The blot was visua-
lized and analyzed as described above.
C-14 uric acid (urate). Radiolabeled C-14 uric acid (Moravek INC, USA) was
dissolved in a stock solution of 2 mM NaOH with a ﬁnal uric acid concentration of
2 mM (either 2 mM hot-radiolabeled uric acid or 1 mM hot and 1 mM cold uric
acid). For oocyte transport experiments, the radiolabeled C-14 uric acid (urate) was
included at various concentrations in ND96 Ringer’s solution (in mM: 96 NaCl, 2
KCl, 2 MgCl2, 5 HEPES, 1.8 CaCl2, pH 7.5) or low Cl− ND96 (in mM: 96 Na
Gluconate, 2 KCl, 2 MgCl2, 5 HEPES, 1.8 CaCl2, pH 7.5).
Urate transport assays. Xenopus oocyte transport experiments were conducted as
previously described14. Oocytes were incubated for 60 or 120min at room tem-
perature in a 150 µM, 300 µM, or 600 µM C-14 urate/ND96 solution. Transport rates
were based on the estimated volume of a single oocyte being 1 µl. After incubation the
oocytes were washed in ice-cold ND96 solution three to ﬁve times to remove any
residual C-14 urate from the oocytes and pooled for scintillation counting: two
oocytes were placed in each scintillation tube with lysis buffer of 200 µl 10%SDS.
Three ml of scintillation ﬂuid (SafetySolve, RPI Corp, USA) was then added and their
counts per minute counted using a Beckman Scintillation counter (LS 5000TA,
Beckman Coulter Inc., USA). For each batch of counting, a set of control vials of
known volume and concentration of C-14 urate was included, allowing for a calcu-
lation of C-14 urate concentrations based on the counts measured in any of the
experimental samples. In a Supplementary analysis of transport rates of the
SLC22A12 mutants, the rate of uptake was further normalized to the expression of
SLC22A12 using western blot. Signiﬁcance was evaluated using a Student’s t-test
comparing the mutant to the wild-type versions of the transporter.
Protein structural modeling and bioinformatics. SLC22A12/URAT1 topology
and transmembrane domains predicted using a constrained Phobius prediction
method and veriﬁed using a HMMTOP analysis65. The 2D topology was drawn
using TOPO2 (http://www.sacs.ucsf.edu/cgi-bin/open-topo2.py). SLC2A trans-
porter NCBI Reference Sequences were obtained from the NCBI and aligned
using MacVector (MacVector INC, USA). The structural model of human
SLC2A9b was constructed in a manner similar to the previously published Long
et al.28. The Wt and variant protein sequence were submitted separately to the I-
Tasser Server at the University of Michigan using the recent crystal structure of
rat SLC2A5 (PDB:4YBQ) as the template66,67. The resulting model had a con-
ﬁdence score (C-score) of +0.42 (scale −5 to +2), indicating a model with a
relatively high conﬁdence based on template alignment and structural similarity.
The modeling of urate as a substrate and the SLC2A9b binding pocket with
predicted hydrogen bonding interactions was based on published docking
studies by Long et al., and putative damaging variants with urate-associated
betas <−1 and > 1 were mapped onto the hSLC2A9 model (Supplementary
Data 24)28.
Code availability. The analysis plans for cohort-level association analyses, meta-
analyses, candidate gene interrogation, and replication of rs150255373 are included
in Supplementary Note 2. The programs that implemented these analysis plans are
available upon request.
Data availability
The summary statistics of the meta-analyses have been submitted to dbGaP accession
phs000930 and can be requested from there.
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